Debra A. Cafaro
Analyst · Jeff Spector from Bank of America Merrill Lynch
Thanks, Lori, and good morning to all of our shareholders and other participants. Thank you so much for joining Ventas' First Quarter 2013 Earnings Call. I'm pleased to discuss the results of another excellent quarter. This morning, Ray Lewis will also discuss our portfolio performance; and our CFO, Rich Schweinhart, will review our financial results. Following our remarks, we'll be pleased to answer your questions. Consistent with our management team's commitment to achieve and sustain excellence for all our stakeholders, Ventas began the year with outstanding growth and property cash flow, normalized FFO per share and dividends. Ventas' balanced, consistent approach of driving growth, while staying strong, diverse and secure, continues to produce outstanding returns for shareholders. Year-to-date, Ventas' total returns exceed 22%, well in excess of both the RMZ and S&P 500 indices. More importantly, our 10-year performance is an exceptional 888%, showing our long-term track record of out-performance. In short, our strategy is working, our team is executing and Ventas' business is great. Some of the highlights of the quarter were: First, normalized FFO with $1.03 per diluted share, representing 16% growth from the first quarter of last year, excluding noncash items in both periods. This increase in FFO flows from both internal and external sources. Same-store cash flow growth in our high-quality, diverse portfolio exceeded 4% in the quarter, and we derived significant benefit from last year's $2.7 billion in accretive investments. Our cash flow growth enabled us to increase our dividend by 8% in the first quarter to an annual rate of $2.68 a share. With a secure payout ratio of 67%, we are well-positioned to continue our record of increasing the dividend at above average levels, a competitive advantage in delivering superior total shareholder return. We successfully completed $200 million of investments during the quarter at initial cash yields approximating 6.5% in high-quality medical office buildings and senior housing assets. We continue to maintain a robust pipeline of attractive additional investment opportunities. At the same time as we are fueling our continued growth, we are also consistent in managing our business with discipline. During the quarter, we took advantage of historically low interest rates to extend our debt maturities by raising $759 million in senior notes, with a 15-year weighted average maturity and a fixed rate of 3.6%. By using the proceeds to pay down our revolver, we also created significant liquidity and shifted more of our capital structure into fixed rate versus floating. At the end of the quarter, our debt-to-enterprise value was an astonishingly good 28%. Recognizing our outstanding credit metrics, scale of $31 billion, consistency, private pay focus and diverse business model, S&P improved its outlook on our corporate credit to positive at the end of March, following similar action by Moody's in December. As planned, and consistent with our risk management approach, we sold portions of the higher-yielding loans we originated in the fourth quarter, at par to sophisticated partners. We expect to complete another $100 million of this activity going forward to manage our aggregate loan investments and our single-borrower exposure. Finally, our asset management and legal teams are pushing toward the finish line, regarding the 89 licensed health care assets whose lease terms expire at the end of this month. We are pleased to report that the lion's share of these transactions and operating transition should be completed by May 1 at the rent and on the terms we previously announced. We expect the remainder be completed, as we said on our last call, by the end of this quarter. We believe that this process is a great example of the proactive, collaborative team execution capabilities at Ventas, resulting in an excellent outcome. Consistent with our expectations when we spoke with you 2 months ago, we are confirming our full year normalized FFO guidance of $3.99 to $4.07 per diluted share. If achieved, the midpoint of our range represents 9% growth per share, including, not excluding, noncash items. We remain comfortable with our full-year guidance range, even though we replaced almost $800 million of floating rate debt with fixed rate debt, and completed over half of our ongoing loan and asset dispositions late in the first quarter. While these actions will reduce normalized FFO in subsequent quarters, we are incredibly well set up to capture the many investment opportunities we see before us. As I said in February, acquisition opportunities abound in our large, fragmented health care and senior housing investment market. We see opportunities to add to our best-in-class senior housing operating portfolio, our medical office building business and a range of triple-net investment across the continuum of care. Our existing liquidity, balance sheet and diversification are highly supportive of continued external growth. While we can never predict the timing or amount of our investment activities, we are excited about continuing to expand our portfolio in a balanced, forward-thinking way to create value for stakeholders. Our team is definitely leaning in as we look to the balance of 2013.